10-K: Vycor Medical Inc. Reports 22% Revenue Increase in 2023, Achieves Positive Cash Operating Income

Vycor Medical, Inc. saw a 22% increase in revenue for its medical device sales in 2023 and achieved positive cash operating income for the year.

Summary

• Vycor Medical, Inc. reported a 22% increase in revenue from product sales, reaching $1,378,598 in 2023, compared to 2022.
• The majority of the revenue growth came from the US market, which saw a 23% increase, while Europe experienced a slight decline.
• The company's gross margin was 90% for 2023, up from 88% in 2022.
• NovaVision, another business unit of Vycor, recorded revenues of $82,006 in 2023, a slight decrease from 2022, with a gross margin of 94%.
• Research and development expenses were $22,558 in 2023, reflecting early-stage product development for the Vycor division.
• Selling, general, and administrative expenses decreased by $135,219 to $1,195,408 in 2023.
• The company generated positive cash flow from operations for the year ended December 31, 2023.
• The company has a working capital deficiency of $3,490,397, which includes related party liabilities of $2,959,485.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.

Sentiment

Score: 4

Explanation: While the company shows positive revenue growth and improved gross margins, the significant working capital deficiency and going concern uncertainty weigh heavily on the overall sentiment. The need for potential capital raising also adds to the negative outlook.

Positives

• Vycor Medical experienced significant revenue growth of 22% in 2023.
• The company achieved a strong gross margin of 90% for Vycor Medical and 94% for NovaVision.
• The company successfully generated positive cash flow from operations in 2023.
• Selling, general, and administrative expenses were reduced by $135,219 in 2023.

Negatives

• NovaVision's revenue decreased slightly by $10,068 in 2023.
• The company has a significant working capital deficiency of $3,490,397.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has a term note for $300,000 to EuroAmerican Investment Corp. with a maturity date of March 31, 2025, and it is not known if a further extension will be available.

Risks

• The company's ability to continue as a going concern is uncertain due to its working capital deficiency and historical losses.
• The company may not have sufficient cash to meet its needs through March 31, 2025, without additional funding.
• There is no guarantee that Fountainhead, the company's largest shareholder, will continue to provide working capital funding.
• The company may have to delay or curtail development or commercialization of products or cease some of its operations if adequate funds are not available.
• The company's debt includes a term note with EuroAmerican Investment Corp. that has a maturity date of March 31, 2025, and it is not known if a further extension will be available.

Future Outlook

The company is focused on increasing market penetration in the US and internationally, continuing new product development, and exploring partnerships for NovaVision. Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

Management Comments

• The Company is continuing to execute on a plan to achieve revenue growth and a reduction in annual cash operating losses.
• Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale.

Industry Context

The company operates in the medical device industry, with a focus on neurosurgery and vision rehabilitation. The company is working to integrate its VBAS product with neuronavigation systems, which is a growing trend in the neurosurgery field. The company is also exploring partnerships to expand the distribution of its NovaVision products, which is a common strategy in the medical device industry.

Comparison to Industry Standards

• Vycor Medical's 22% revenue growth is a positive sign, but it is important to compare this to the growth rates of other medical device companies in the neurosurgery space. Companies like Medtronic and Stryker are major players in this market, and their growth rates can serve as a benchmark.
• The company's gross margin of 90% for Vycor Medical is relatively high, which is typical for medical device companies. However, it is important to compare this to the gross margins of similar companies to assess its competitiveness.
• The company's working capital deficiency of $3,490,397 is a significant concern and needs to be addressed. Many medical device companies rely on external funding to support their operations, but it is important to ensure that the company has a sustainable financial model.
• The company's decision to close the German operations of NovaVision and move to a licensed business model is a common strategy for companies looking to reduce costs and focus on core markets. This is similar to how other companies like Boston Scientific and Abbott operate in international markets.

Related Party Transactions

• Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead which owned, at December 31, 2023, 62.3% of the Company's Common Stock and 69.7% of the Company's Series D Preferred Stock.
• Adrian Liddell, Chairman, is a consultant to Fountainhead.
• Peter Zachariou owns 0.15% of the Company's Common Stock and 25.7% of the Company's Series D Preferred Stock.
• During the years ended December 31, 2023 and 2022, the Company issued unsecured loan notes to Fountainhead for a total of $0 and $172,500, respectively.
• During the years ended December 31, 2023 and 2022, the Company accrued interest on related party loans of $49,515 and $39,563, respectively.
• During each of the years ended December 31, 2023 and 2022, the Company accrued an aggregate of $324,370 of Preferred D Stock dividends, of which $226,037 was regarding Fountainhead and $83,386 was regarding Peter Zachariou.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential need for additional funding.
• Employees may be impacted by potential delays or curtailment of operations if adequate funds are not available.
• Customers may be affected by potential disruptions in product availability or service if the company faces financial difficulties.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company will continue to work with neuronavigation companies to seek ways to further integrate the VBAS with neuronavigation.
• The company will explore with neurosurgeons and focus groups additional selected development work targeted at increasing the ease and applicability of our products to additional common procedures.
• The company will continue to seek partnerships for the distribution of its NovaVision products.
• The company may consider seeking additional equity or debt funding.

Key Dates

Keywords

Vycor Medical, NovaVision, medical devices, neurosurgery, vision rehabilitation, revenue growth, cash flow, working capital, ISO 13485, MDSAP